Mild Cognitive Impairment

6
Pipeline Programs
12
Companies
12
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

11 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
2 programs
1
AriceptPhase 41 trial
group cognitive interventionN/A1 trial
Active Trials
NCT01358955Completed293Est. Jan 2013
NCT00934375Completed145Est. Sep 2007
Precision BioSciences
1 program
1
Atorvastatin Oral TabletPhase 21 trial
Active Trials
NCT04765137Recruiting20Est. Dec 2026
FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
1
T-817MAPhase 21 trial
Active Trials
NCT04191486CompletedEst. Mar 2023
Function Therapeutics
Function TherapeuticsWI - Milwaukee
1 program
1
The Computerized Functional Skills Assessment and Training ProgramPhase 21 trial
Active Trials
NCT04679441Active Not RecruitingEst. May 2023
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
DabigatranPhase 11 trial
Active Trials
NCT03752294Withdrawn0Est. May 2022
BrainsWay
BrainsWayJerusalem, Israel
1 program
1
H-Coil Deep TMSPhase 11 trial
Active Trials
NCT01464515UnknownEst. Jan 2021
Eureka Therapeutics
Eureka TherapeuticsCA - Emeryville
1 program
Brain Blossom - Gamified Differential Outcome TrainingN/A1 trial
Active Trials
NCT06399978Not Yet RecruitingEst. Jan 2025
Novartis
NovartisBASEL, Switzerland
1 program
Clinical Pathway for Alzheimer's Disease in China (CPAD)N/A1 trial
Active Trials
NCT01779310Completed1,024Est. Apr 2013
C2N Diagnostics
C2N DiagnosticsMO - St. Louis
1 program
Digital MoCAN/A1 trial
Active Trials
NCT07041450Recruiting500Est. Mar 2026
Providence Therapeutics
1 program
Nonlinear dynamical neurofeedbackN/A1 trial
Active Trials
NCT06762522Not Yet RecruitingEst. Jan 2026
Design Therapeutics
1 program
WalkasinsN/A1 trial
Active Trials
NCT05723822CompletedEst. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiAricept
Function TherapeuticsThe Computerized Functional Skills Assessment and Training Program
Precision BioSciencesAtorvastatin Oral Tablet
FUJIFILM PharmaT-817MA
BrainsWayH-Coil Deep TMS
Boehringer IngelheimDabigatran
C2N DiagnosticsDigital MoCA
Providence TherapeuticsNonlinear dynamical neurofeedback
Eureka TherapeuticsBrain Blossom - Gamified Differential Outcome Training
Design TherapeuticsWalkasins
NovartisClinical Pathway for Alzheimer's Disease in China (CPAD)
Eisaigroup cognitive intervention

Clinical Trials (12)

Total enrollment: 1,982 patients across 12 trials

NCT00934375EisaiAricept

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Start: Feb 2006Est. completion: Sep 2007145 patients
Phase 4Completed
NCT04679441Function TherapeuticsThe Computerized Functional Skills Assessment and Training Program

A Novel Computer-Based Functional Skills Assessment and Training Program

Start: Aug 2021Est. completion: May 2023
Phase 2Active Not Recruiting
NCT04765137Precision BioSciencesAtorvastatin Oral Tablet

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Start: May 2021Est. completion: Dec 202620 patients
Phase 2Recruiting
NCT04191486FUJIFILM PharmaT-817MA

Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Start: Dec 2019Est. completion: Mar 2023
Phase 2Completed
NCT01464515BrainsWayH-Coil Deep TMS

Efficiency of Deep Transcranial Magnetic Stimulation on Patients With Mild Cognitive Impairment

Start: Jan 2021Est. completion: Jan 2021
Phase 1Unknown
NCT03752294Boehringer IngelheimDabigatran

A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

Start: May 2019Est. completion: May 20220
Phase 1Withdrawn
NCT07041450C2N DiagnosticsDigital MoCA

Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers

Start: Mar 2025Est. completion: Mar 2026500 patients
N/ARecruiting
NCT06762522Providence TherapeuticsNonlinear dynamical neurofeedback

Exploring Feasibility, Acceptability and Impact of Using Neurofeedback with Persons with Mild Cognitive Impairment

Start: Jan 2025Est. completion: Jan 2026
N/ANot Yet Recruiting
NCT06399978Eureka TherapeuticsBrain Blossom - Gamified Differential Outcome Training

The Feasibility and Effect of Digital Cognitive Training in Mild Cognitive Impairment

Start: May 2024Est. completion: Jan 2025
N/ANot Yet Recruiting
NCT05723822Design TherapeuticsWalkasins

Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments

Start: Feb 2023Est. completion: Mar 2023
N/ACompleted
NCT01779310NovartisClinical Pathway for Alzheimer's Disease in China (CPAD)

Clinical Pathway for Alzheimer's Disease in China (CPAD)

Start: Nov 2012Est. completion: Apr 20131,024 patients
N/ACompleted
NCT01358955Eisaigroup cognitive intervention

Efficacy Study of Cognitive Intervention in Amnestic Mild Cognitive Impairment

Start: Mar 2011Est. completion: Jan 2013293 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,982 patients
12 companies competing in this space